11 results
ARS
2023 FY
TARS
Tarsus Pharmaceuticals Inc
26 Apr 24
Annual report to shareholders
4:27pm
action could have a material adverse effect on our business, market acceptance of our products, and our reputation. 23
Our product candidates … effect upon our reputation, business, operations or financial condition, whether due to a loss of our trade secrets or other proprietary information
ARS
2022 FY
TARS
Tarsus Pharmaceuticals Inc
26 Apr 23
Annual report to shareholders
4:08pm
a material adverse effect on our business, market acceptance of our products, and our reputation. Our product candidates are considered small molecule … in our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition, whether
10-K
2020 FY
TARS
Tarsus Pharmaceuticals Inc
31 Mar 21
Annual report
5:01pm
, market acceptance of our products, and our reputation.
Our product candidates are considered small molecule drugs and must be approved by the FDA through … be sued and held liable for harm caused to patients; and
our reputation may suffer and there may be resulting harm to physician or patient acceptance
10-Q
h65zdm9
24 Nov 20
Quarterly report
9:27pm
424B4
5rl xujhwe
16 Oct 20
Prospectus supplement with pricing info
4:40pm
S-1/A
r4wmpr24by38
9 Oct 20
IPO registration (amended)
5:16pm
S-1
q01nj1c
25 Sep 20
IPO registration
5:25pm
DRS/A
m3umabop4 ix
14 Sep 20
Draft registration statement (amended)
12:00am
DRS
tt7wajap
7 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next